Voluntary running does not reduce neuroinflammation or improve non-cognitive behavior in the 5xFAD mouse model of Alzheimer’s disease
Open Access
- 28 January 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-10
Abstract
Physical exercise has been suggested to reduce the risk of developing Alzheimer’s disease (AD) as well as ameliorate the progression of the disease. However, we recently published results from two large epidemiological studies showing no such beneficial effects on the development of AD. In addition, long-term, voluntary running in the 5xFAD mouse model of AD did not affect levels of soluble amyloid beta (Aβ), synaptic proteins or cognitive function. In this follow-up study, we investigate whether running could impact other pathological aspects of the disease, such as insoluble Aβ levels, the neuroinflammatory response and non-cognitive behavioral impairments. We investigated the effects of 24 weeks of voluntary wheel running in female 5xFAD mice (n = 30) starting at 2–3 months of age, before substantial extracellular plaque formation. Running mice developed hindlimb clasping earlier (p = 0.009) compared to sedentary controls. Further, running exacerbated the exploratory behavior in Elevated plus maze (p = 0.001) and anxiety in Open field (p = 0.024) tests. Additionally, microglia, cytokines and insoluble Aβ levels were not affected. Taken together, our findings suggest that voluntary wheel running is not a beneficial intervention to halt disease progression in 5xFAD mice.Keywords
Funding Information
- The Royal Physiographic Society
- MULTIPARK
- swedish alzheimer foundation
- Swedish brain foundation
- Crafoord Foundation
- Swedish Dementia Association
- Swedish Medical Research Council
- Medical Faculty at Lund University
This publication has 54 references indexed in Scilit:
- Integration of Alzheimer’s disease genetics and myeloid genomics reveals novel disease risk mechanismsbioRxiv, 2019
- Differences between the behavioral and psychological symptoms of Alzheimer's disease and Parkinson's diseaseJournal of the Neurological Sciences, 2016
- Neuroinflammation in Alzheimer's disease: Current evidence and future directionsAlzheimer's & Dementia, 2016
- Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s diseaseBrain, 2015
- Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementiaAlzheimer's & Dementia, 2014
- Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-α Expression for Microglial Aβ PhagocytosisJournal of Neuroscience, 2011
- Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET studyNeurobiology of Disease, 2008
- Neuropsychiatric symptoms in the dementiasCurrent Opinion in Neurology, 2002
- Occurrence of Interleukin‐6 in Cortical Plaques of Alzheimer's Disease Patients May Precede Transformation of Diffuse into Neuritic PlaquesaAnnals of the New York Academy of Sciences, 1996
- Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.Proceedings of the National Academy of Sciences, 1989